“With India achieving high vaccination rates in 2021 and 2022, coupled with the emergence of new mutant variant strains, the demand for previous vaccines diminished significantly.Consequently, since December 2021, we have stopped the manufacturing and supply of additional doses of Covishield,” a spokesperson from the SII said on Wednesday.
“Have disclosed all side effects in packaging”
In response to the side effects of the vaccine, the Serum Institute of India has said that they have disclosed all the rare to very rare side effects in its packaging since 2021. “We fully understand the ongoing concerns and it’s crucial to emphasize our commitment to transparency and safety. From the outset, we have disclosed all rare to very rare side effects, including Thrombosis with Thrombocytopenia Syndrome, in the packaging insert in 2021,” the SII spokesperson said.
Concerns around the potential health risks of the vaccine grew after AstraZeneca admitted it in court documents about a rare side effect which is Thrombosis with thrombocytopenia syndrome or TTS. Thrombosis with thrombocytopenia syndrome (TTS) is a rare but serious condition characterized by blood clot formation combined with low platelet levels. Typically linked to certain COVID-19 vaccines, TTS manifests as blood clots in unusual sites such as the brain or abdomen, accompanied by reduced platelet counts. Symptoms include severe headaches, abdominal pain, and neurological deficits. Prompt medical attention is crucial as TTS can lead to life-threatening complications like stroke or organ damage. Treatment often involves hospitalization, blood thinners, and close monitoring.
